STANDING COMMITTEE OF THE EFTA STATES

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the first half of 2011

(2012/C 44/05)

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January-30 June 2011, at their meeting on 30 September 2011:

Annex I List of new marketing authorisations

Annex II List of renewed marketing authorisations

Annex III List of extended marketing authorisations

Annex IV List of withdrawn marketing authorisations

Annex V List of suspended marketing authorisations

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January-30 June 2011:

EU-Number	Product	Country	Date of authorisation
EU/1/09/578/001	Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) Glaxo-SmithKline Biologicals	Iceland	29.4.2011
EU/1/10/635/001-014	Olanzapin Apotex	Norway	14.2.2011
EU/1/10/639/001-030	Telmisartan Actavis	Norway	17.3.2011
EU/1/10/641/001	Ruconest	Iceland	24.1.2011
EU/1/10/642/001-004	Ibandronic Acid Teva	Iceland	17.1.2011
EU/1/10/647/001-002	Myclausen	Iceland	21.1.2011
EU/1/10/647/001-028	Twynsta	Iceland	21.1.2011
EU/1/10/650/001-015	Clopidogrel Teva Generics BV	Iceland	1.2.2011
EU/1/10/651/001-015	Clopidogrel HCS	Iceland	1.2.2011
EU/1/10/654/001-004	Leflunomide ratiopharm	Iceland	14.3.2011
EU/1/10/656/001-006	Possia	Iceland	13.1.2011
EU/1/10/656/001-006	Possia	Norway	25.1.2011
EU/1/10/657/001-002	Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Dia	Iceland	14.3.2011
EU/1/10/657/001-002	Prepandemic Influenza Vaccine	Norway	3.1.2011
EU/1/10/658/001-002	Aflunov	Iceland	14.3.2011
EU/1/10/658/001-002	Aflunov	Norway	3.1.2011
EU/1/10/659/001-010	Iasibon	Iceland	14.2.2011
EU/1/10/659/001-010	Iasibon	Norway	17.2.2011
EU/1/10/659/001-010	Iasibon	Liechtenstein	28.2.2011
EU/1/10/660/001-002	Potactasol	Iceland	16.3.2011
EU/1/10/660/001-002	Potactasol	Liechtenstein	28.2.2011
EU/1/10/661/001-002	Fluenz	Iceland	16.3.2011
EU/1/10/661/001-002	Fluenz	Liechtenstein	28.2.2011
EU/1/10/662/001-002	Docetaxel Teva Pharma	Iceland	17.2.2011

EU-Number	Product	Country	Date of authorisation
EU/1/10/662/001-002	Docetaxel Teva Pharma	Liechtenstein	28.2.2011
EU/1/10/662/001-002	Docetaxel Teva Pharma	Norway	17.3.2011
EU/1/10/662/001-002	Docetaxel Teva Pharma	Norway	17.3.2011
EU/1/10/663/001-002	Lamivudine/Zidovudine Teva	Norway	31.3.2011
EU/1/10/663/001-002	Lamivudine/Zidovudine Teva	Liechtenstein	30.4.2011
EU/1/10/664/001	Pumarix	Iceland	8.4.2011
EU/1/10/664/001	Pumarix	Norway	13.4.2011
EU/1/10/664/001	Pumarix	Liechtenstein	30.4.2011
EU/1/10/665/001-004	Entacapone Teva	Iceland	21.3.2011
EU/1/10/665/001-004	Entacapone Teva	Norway	4.4.2011
EU/1/10/665/001-004	Entacapone Teva	Liechtenstein	30.4.2011
EU/1/11/666/001-003	Libertek	Iceland	24.3.2011
EU/1/11/666/001-003	Libertek	Norway	15.3.2011
EU/1/11/666/001-003	Libertek	Liechtenstein	30.4.2011
EU/1/11/667/001-003	Esbriet	Liechtenstein	30.4.2011
EU/1/11/667/001-003	Esbriet	Iceland	25.3.2011
EU/1/11/667/001-003	Esbriet	Norway	15.3.2011
EU/1/11/667/001-003	Esbriet	Norway	15.3.2011
EU/1/11/668/001-003	Daliresp	Iceland	12.4.2011
EU/1/11/668/001-003	Daliresp	Norway	15.3.2011
EU/1/11/668/001-003	Daliresp	Liechtenstein	30.4.2011
EU/1/11/669/001-004	Teysuno	Iceland	12.4.2011
EU/1/11/669/001-004	Teysuno	Norway	24.5.2011
EU/1/11/669/001-004	Teysuno	Liechtenstein	30.4.2011
EU/1/11/671/001	Xiapex	Iceland	28.3.2011
EU/1/11/671/001	Xiapex	Norway	31.3.2011
EU/1/11/671/001	Xiapex	Liechtenstein	30.4.2011

EU-Number	Product	Country	Date of authorisation
EU/1/11/672/001-006	Xeplion	Iceland	8.4.2011
EU/1/11/672/001-006	Xeplion	Norway	5.4.2011
EU/1/11/672/001-006	Xeplion	Liechtenstein	30.4.2011
EU/1/11/673/001-024	Ifirmacombi	Iceland	4.4.2011
EU/1/11/673/001-024	Ifirmacombi	Norway	6.4.2011
EU/1/11/673/001-024	Ifirmacombi	Liechtenstein	30.4.2011
EU/1/11/674/001-010	Repso	Iceland	13.4.2011
EU/1/11/674/001-010	Repso	Norway	26.4.2011
EU/1/11/674/001-010	Repso	Liechtenstein	30.4.2011
EU/1/11/675/001-0010	Leflunomide Teva	Iceland	8.4.2011
EU/1/11/675/001-010	Lefluomide Teva	Norway	11.4.2011
EU/1/11/675/001-010	Leflunomid Teva	Liechtenstein	30.4.2011
EU/1/11/676/001	Jevtana	Iceland	12.4.2011
EU/1/11/676/001	Jevtana	Norway	6.4.2011
EU/1/11/676/001	Jevtana	Liechtenstein	30.4.2011
EU/1/11/677/001-004	Gilenya	Iceland	13.4.2011
EU/1/11/677/001-004	Gilenya	Norway	28.3.2011
EU/1/11/677/001-004	Gilenya	Liechtenstein	30.4.2011
EU/1/11/678/001-002	Halaven	Iceland	14.4.2011
EU/1/11/678/001-002	Halaven	Norway	6.4.2011
EU/1/11/678/001-002	Halaven	Liechtenstein	30.4.2011
EU/1/11/679/001-006	Pravafenix	Iceland	10.5.2011
EU/1/11/679/001-006	Pravafenix	Norway	11.5.2011
EU/1/11/679/001-006	Pravafenix	Liechtenstein	30.4.2011
EU/1/11/680/001-080	Riprazo HCT	Iceland	29.4.2011
EU/1/11/680/001-080	Riprazo HCT	Norway	24.5.2011
EU/1/11/680/001-080	Riprazo HCT	Liechtenstein	30.4.2011
EU/1/11/681/001-013	Trobalt	Iceland	19.4.2011
EU/1/11/681/001-013	Trobalt	Norway	4.4.2011
EU/1/11/681/001-013	Trobalt	Liechtenstein	30.6.2011

EU-Number	Product	Country	Date of authorisation
EU/1/11/681/001-013	Trobalt	Liechtenstein	30.4.2011
EU/1/11/682/001	Methylthioninium chloride Proveblue	Iceland	6.6.2011
EU/1/11/682/001	Methylhiononininium chloride Proveblue	Norway	27.6.2011
EU/1/11/682/001	Methylthioninchlorid Proveblue	Liechtenstein	30.6.2011
EU/1/11/686/001-056	Rasilamlo	Iceland	12.5.2011
EU/1/11/686/001-056	Rasilamlo	Norway	24.5.2011
EU/1/11/686/001-056	Rasilamlo	Liechtenstein	30.4.2011
EU/1/11/687/001-012	Hizentra	Iceland	12.5.2011
EU/1/11/687/001-012	Hizentra	Norway	9.5.2011
EU/1/11/687/001-012	Hizentra	Liechtenstein	30.4.2011
EU/1/11/688/001	Cinryze	Iceland	28.6.2011
EU/1/11/688/001	Cinryze	Norway	27.6.2011
EU/1/11/691/001-005	Eliquis	Norway	31.5.2011
EU/1/11/691/001-005	Eliquis	Liechtenstein	30.6.2011
EU/1/11/692/001	Yellox	Iceland	28.6.2011
EU/1/11/692/001	Yellox	Norway	10.6.2011
EU/1/11/692/001	Yellox	Liechtenstein	30.6.2011
EU/1/11/693/001-016	Rivastigmine Actavis	Iceland	28.6.2011
EU/1/11/693/001-016	Rivastigmine Actavis	Liechtenstein	30.6.2011
EU/1/190/649/001-016	Clopidogrel Teva Pharma BV	Iceland	30.6.2011
EU/1/98/058/001-002	Lamivudine/Zidovudine Teva	Iceland	12.4.2011
EU/1/98/058/001-002	Lamivudine	Norway	31.3.2011
EU/2/11/120/001-003	Zulvac 1 + 8 Ovis	Liechtenstein	30.4.2011
EU/2/11/126/001	MS-H Impfstoff	Liechtenstein	30.6.2011
EU/2/10/107/001-014	Veraflox	Iceland	10.5.2011
EU/2/10/107/001-014	Veraflox	Norway	24.6.2011
EU/2/10/107/001-014	Veraflox	Liechtenstein	30.4.2011
EU/2/10/109/001-009	RHINISENG	Norway	3.1.2011
EU/2/10/110/001-002	Coxevac	Iceland	26.1.2011
EU/2/10/111/001-004	Meloxoral	Iceland	14.3.2011

EU-Number	Product	Country	Date of authorisation
EU/2/10/111/001-004	Meloxoral	Norway	3.1.2011
EU/2/10/112/001-005	BTVPUR ALSap 1	Iceland	10.2.2011
EU/2/10/112/001-005	BTVPUR ALSap 1	Liechtenstein	28.2.2011
EU/2/10/113/001-005	BTVPUR ALSap 1-8	Iceland	10.2.2011
EU/2/10/113/001-005	BTVPUR ALSap 1-8	Liechtenstein	28.2.2011
EU/2/10/114/001-002	Hiprabovis IBR Marker Live	Iceland	16.3.2011
EU/2/10/114/001-002	Hiprabovis IBR Marker Live	Norway	9.2.2011
EU/2/10/114/001-002	Hiprabovis IBR Marker Live	Liechtenstein	28.2.2011
EU/2/10/115/001-010	Comfortis	Iceland	22.3.2011
EU/2/10/115/001-010	Comfortis	Norway	22.2.2011
EU/2/10/115/001-010	Comfortis	Liechtenstein	30.4.2011
EU/2/10/115/001-010	Comfortis	Norway	22.2.2011
EU/2/10/116/001-004	Melosus	Iceland	24.3.2011
EU/2/10/116/001-004	Melosus	Norway	14.4.2011
EU/2/10/116/001-004	Melosus	Liechtenstein	30.4.2011
EU/2/10/117/001-002	Purevax Rabies	Iceland	21.3.2011
EU/2/10/117/001-002	Purevax Rabies	Norway	4.4.2011
EU/2/10/117/001-002	Purevax Rabies	Liechtenstein	30.4.2011
EU/2/10/118/001-014	Activyl	Iceland	21.3.2011
EU/2/10/118/001-014	Activyl	Norway	1.4.2011
EU/2/10/118/001-014	Activyl	Liechtenstein	30.4.2011
EU/2/10/119/001-012	Cimalgex	Iceland	21.3.2011
EU/2/10/119/001-012	Cimalgex	Norway	1.4.2011
EU/2/108/001-005	BTVPUR ALSap 2-4 0.72 U.SN	Iceland	10.2.2011
EU/2/11/120/001-003	Zulvac 1 + 8 Ovis	Iceland	13.4.2011
EU/2/11/120/001-003	Zulvac 1 + 8 Ovis	Norway	18.4.2011
EU/2/11/121/001-009	CaniLeish	Iceland	13.4.2011
EU/2/11/121/001-009	CaniLeish	Norway	11.4.2011
EU/2/11/121/001-009	CaniLeish	Liechtenstein	30.4.2011
EU/2/11/123/001-002	Procox	Iceland	28.6.2011

EU-Number	Product	Country	Date of authorisation
EU/2/11/123/001-002	Procox	Norway	20.6.2011
EU/2/11/123/001-002	Procox	Liechtenstein	30.6.2011
EU/2/11/124/001-008	Zuprevo	Iceland	6.6.2011
EU/2/11/124/001-008	Zuprevo	Liechtenstein	30.6.2011
EU/2/11/125/001-008	Certifect	Iceland	6.6.2011
EU/2/11/125/001-008	Certificet	Liechtenstein	30.6.2011
EU/2/11/126/001	MS-H-vaccine	Iceland	28.6.2011

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January-30 June 2011:

EU-Number	Product	Country	Date of authorisation
EU/1/00/135/001-002	DaTSCAN	Iceland	14.3.2011
EU/1/00/149/001	Panretin	Iceland	18.1.2011
EU/1/00/156/002-004	Trizivir	Iceland	14.2.2011
EU/1/00/166/001-003	NeuroBloc	Iceland	15.2.2011
EU/1/00/166/001-003	NeuroBloc	Norway	15.2.2011
EU/1/00/167/001-008	Prevenar	Iceland	25.3.2011
EU/1/00/167/001-008	Prevenar	Norway	3.3.2011
EU/1/00/167/001-008	Prevenar	Liechtenstein	28.2.2011
EU/1/00/173/001-003	Vaniqa	Iceland	15.4.2011
EU/1/01/171/001, 007-010, 013-014	Rapamune	Iceland	21.2.2011
EU/1/01/171/001, EU/1/01/171/007-010 EU/1/01/171/013-014	Rapamune	Norway	2.2.2011
EU/1/01/172/001-008	Kaletra	Iceland	21.3.2011
EU/1/01/172/001-008	Kaletra	Norway	27.4.2011
EU/1/01/172/001-008	Kaletra	Liechtenstein	30.4.2011
EU/1/01/173/001-003	Vaniqa	Norway	3.5.2011
EU/1/01/173/001-003	Vaniqa	Liechtenstein	30.4.2011
EU/1/01/179/001	Osigraft	Iceland	17.5.2011
EU/1/01/179/001	Osigraft	Norway	15.6.2011
EU/1/01/179/001	Osigraft	Liechtenstein	30.6.2011
EU/1/01/183/001&004-005, 007-008, 011, 013, 015, 018-032	HBVAXPRO	Iceland	18.4.2011
EU/1/01/183/001, EU/1/01/183/004-005 EU/1/01/183/007-008, EU/1/01/183/011 EU/1/01/183/013, EU/1/01/183/015 EU/1/01/183/018-032	HBVAXPRO	Norway	14.4.2011
EU/1/01/187/001	DepoCyte	Iceland	23.6.2011
EU/1/01/187/001	DepoCyte	Liechtenstein	30.6.2011
EU/1/01/191/001-005	Ketek 400 mg	Iceland	9.6.2011
EU/1/01/191/001-005	Ketek	Norway	31.5.2011
EU/1/01/191/001-005	Ketek	Liechtenstein	30.6.2011
EU/1/01/193/001-002	MabCampath	Iceland	23.6.2011
EU/1/01/193/001-002	MabCampath	Norway	15.6.2011
EU/1/05/312/001	Xyrem	Iceland	14.1.2011
EU/1/05/313/001-009	Ablavar	Iceland	28.1.2011

EU-Number	Product	Country	Date of authorisation
EU/1/05/314/001	Kepivance	Iceland	17.1.2011
EU/1/05/315/001-002	Aptivus	Iceland	27.1.2011
EU/1/05/320/001	Noxafil	Iceland	18.1.2011
EU/1/05/322/001	Yttriga	Iceland	18.3.2011
EU/1/05/322/001	Yttriga	Norway	20.1.2011
EU/1/05/322/001	Yttriga	Liechtenstein	28.2.2011
EU/1/05/323/001-013	ProQuad	Iceland	15.4.2011
EU/1/05/323/001-013	ProQuad	Norway	6.4.2011
EU/1/05/323/001-013	ProQuad	Liechtenstein	30.4.2011
EU/1/05/324/001-002	Naglazyme	Iceland	23.3.2011
EU/1/05/324/001-002	Naglazyme	Norway	7.2.2011
EU/1/05/324/001-002	Naglazyme	Liechtenstein	28.2.2011
EU/1/05/325/002	Macugen	Iceland	15.2.2011
EU/1/05/325/002	Macugen	Norway	1.2.2011
EU/1/05/325/002	Macugen	Liechtenstein	28.2.2011
EU/1/05/328/001-004	Cubicin	Iceland	14.2.2011
EU/1/05/328/001-004	Cubicin	Norway	11.1.2011
EU/1/05/329/001-006	Kiovig	Iceland	24.2.2011
EU/1/05/329/001-006	Kiovig	Norway	2.2.2011
EU/1/05/329/001-006	Kiovig	Liechtenstein	28.2.2011
EU/1/05/330/001-011	Rotarix	Iceland	22.3.2011
EU/1/05/330/001-011	Rotarix	Norway	13.5.2011
EU/1/05/331/001-055	Neupro	Iceland	15.2.2011
EU/1/05/331/001-055	Neupro	Norway	10.1.2011
EU/1/06/332/001-009	Omnitrope	Iceland	28.6.2011
EU/1/06/332/001-009	Omnitrope	Norway	5.4.2011
EU/1/06/332/001-009	Omnitrope	Liechtenstein	30.4.2011
EU/1/06/333/001-003	Myozyme	Iceland	20.4.2011
EU/1/06/333/001-003	Myozyme	Norway	22.3.2011
EU/1/06/333/001-003	Myozyme	Liechtenstein	30.4.2011
EU/1/06/334/001-005	Evoltra	Iceland	18.4.2011
EU/1/06/334/001-005	Evoltra	Norway	25.5.2011
EU/1/06/334/001-005	Evoltra	Liechtenstein	30.4.2011
EU/1/06/335/001	Valtropin	Iceland	12.5.2011
EU/1/06/335/001	Valtropin	Norway	3.6.2011
EU/1/06/335/001	Valtropin	Liechtenstein	30.4.2011
EU/1/06/336/001	Tygacil	Norway	31.5.2011

EU-Number	Product	Country	Date of authorisation
EU/1/06/336/001	Tygacil	Liechtenstein	30.6.2011
EU/1/06/337/001-013	M-M-RVAXPRO	Iceland	16.5.2011
EU/1/06/337/001-013	M-M-RVAXPRO	Norway	31.5.2011
EU/1/06/337/001-013	M-M-RVAXPRO	Liechtenstein	30.6.2011
EU/1/06/338/001-003	DuoTrav	Iceland	21.1.2011
EU/1/06/339/001-002	Preotact	Iceland	11.5.2011
EU/1/06/339/001-002	Preotact	Liechtenstein	30.4.2011
EU/1/06/341/001-013	Zostavax	Iceland	18.4.2011
EU/1/06/341/001-013	Zostavax	Liechtenstein	30.4.2011
EU/1/06/343/001-007	Baraclude	Iceland	23.6.2011
EU/1/06/343/001-007	Baraclude	Liechtenstein	30.6.2011
EU/1/06/346/001	Tysabri	Iceland	27.6.2011
EU/1/06/348/001-002	RotaTeq	Iceland	23.6.2011
EU/1/06/348/001-002	RotaTeq	Norway	17.6.2011
EU/1/06/348/001-002	RotaTeq	Liechtenstein	28.2.2011
EU/1/06/354/001-011	Competact	Iceland	24.6.2011
EU/1/06/354/001-011	Competact	Norway	23.6.2011
EU/1/06/354/001-011	Competact	Liechtenstein	30.6.2011
EU/1/06/360/001-013	Champix	Liechtenstein	30.6.2011
EU/1/06/367/001-012	Diacomit	Iceland	11.2.2011
EU/1/06/367/001-012	Diacomit	Norway	15.2.2011
EU/1/06/367/001-012	Diacomit	Liechtenstein	28.2.2011
EU/1/07/423/001-003	Vectibix	Iceland	15.2.2011
EU/1/07/423/001-003	Vectibix	Norway	25.1.2011
EU/1/07/440/001-003	Tyverb	Norway	3.6.2011
EU/1/10/625/001	Arzerra	Iceland	22.2.2011
EU/1/10/625/001-002	Arzerra	Norway	17.2.2011
EU/1/10/625/001-002	Arzerra	Liechtenstein	28.2.2011
EU/1/10/628/001-004	Votrient	Iceland	6.6.2011
EU/1/183/001, 004-005, 007-008, 011, 013, 015, 018-032	HBVAXPRO	Liechtenstein	30.4.2011
EU/1/96/009/001-008	Zerit	Iceland	16.5.2011
EU/1/96/009/001-009	Zerit	Norway	6.5.2011
EU/1/96/009/001-009	Zerit	Liechtenstein	30.4.2011
EU/2/00/026/001-004	Porcilis AR-T DF	Norway	3.1.2011
EU/2/00/026/001-006	Porcilis AR-T DF	Iceland	17.1.2011
EU/2/04/045/001-007	Previcox	Norway	18.4.2011

EU-Number	Product	Country	Date of authorisation
EU/2/04/048/001-002	Purevax RCP FeLV	Norway	13.4.2011
EU/2/04/049/001-002	Purevax RCCh	Norway	13.4.2011
EU/2/04/050/001-002	Purevax RCPCh	Norway	13.4.2011
EU/2/04/051/001-002	Purevax RC	Norway	13.4.2011
EU/2/04/052/001-002	Purevax RCP	Norway	13.4.2011
EU/2/06/058/004	Flexicam	Iceland	8.4.2011
EU/2/06/058/004	Flexicam	Norway	26.4.2011
EU/2/06/058/004	Flexicam	Liechtenstein	30.4.2011
EU/2/06/059/001	Convenia	Iceland	27.6.2011

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January-30 June 2011:

EU-Number	Product	Country	Date of authorisation
EU/1/01/185/100-111	Aranesp	Iceland	15.4.2011
EU/1/01/194/003-004	INOmax	Iceland	15.4.2011
EU/1/02/227/003	Neulasta	Liechtenstein	30.4.2011
EU/1/06/332/010-012	Omnitrope	Iceland	16.6.2011
EU/1/06/332/010-012	Omnitrope	Liechtenstein	30.6.2011
EU/1/06/354/010-011	Competact	Liechtenstein	28.2.2011
EU/1/06/354/012	Competact	Liechtenstein	30.6.2011
EU/1/06/370/037-039	Exforge	Liechtenstein	28.2.2011
EU/1/06/371/037-039	Dafiro	Liechtenstein	28.2.2011
EU/1/06/373/037-039	Imprida	Liechtenstein	28.2.2011
EU/1/07/387/014-026	Advagraf	Liechtenstein	30.6.2011
EU/1/07/397/002-004	Siklos	Iceland	25.3.2011
EU/1/07/397/002-004	Siklos	Norway	5.4.2011
EU/1/07/397/002-004	Siklos	Liechtenstein	30.4.2011
EU/1/07/401/012-015	Alli	Iceland	16.2.2011
EU/1/07/401/012-015	Alli	Norway	26.1.2011
EU/1/07/404/006-008	Flebogamma DIF	Iceland	17.2.2011
EU/1/07/404/006-008	Flebogamma DIF	Norway	14.1.2011
EU/1/07/404/006-008	Flebogamma DIF	Liechtenstein	28.2.2011
EU/1/07/407/021-040	Sprimeo	Liechtenstein	30.4.2011
EU/1/07/410/027-052	Binocrit	Liechtenstein	30.4.2011
EU/1/07/411/027-052	Epoetin alfa Hexal	Liechtenstein	30.4.2011
EU/1/07/420/002	Cyanokit	Iceland	20.1.2011
EU/1/07/420/002	Cyanokit	Norway	14.2.2011
EU/1/07/422/005-006	Tasigna	Iceland	23.3.2011
EU/1/07/422/005-006	Tasigna	Norway	21.1.2011
EU/1/07/422/005-006	Tasigna	Liechtenstein	28.2.2011
EU/1/07/438/005-006	Myfenax	Liechtenstein	30.6.2011
EU/1/07/439/005-006	Mycophenole mofetil Teva	Liechtenstein	30.6.2011

EU-Number	Product	Country	Date of authorisation
EU/1/08/461/002	Firazyr	Liechtenstein	30.4.2011
EU/1/08/490/017-024	Pramipexole Teva	Liechtenstein	30.6.2011
EU/1/09/511/005	Conbriza	Liechtenstein	30.4.2011
EU/1/09/535/015-016	Grepid	Liechtenstein	28.2.2011
EU/1/09/545/011-015	Onglyza	Iceland	14.4.2011
EU/1/09/545/011-015	Onglyza	Norway	25.3.2011
EU/1/09/545/011-015	Onglyza	Liechtenstein	30.4.2011
EU/1/09/581/003-008	Resolor	Liechtenstein	28.2.2011
EU/1/10/614/002	Menveo	Liechtenstein	30.4.2011
EU/1/96/022/035-040	Zyprexa	Liechtenstein	28.2.2011
EU/1/97/033/005-006	Avonex	Liechtenstein	30.6.2011
EU/1/99/103/005	ReFacto AF	Iceland	6.6.2011
EU/1/99/103/005-008	ReFacto AF	Norway	1.6.2011
EU/1/99/103/005-008	ReFacto AF	Liechtenstein	30.6.2011
EU/2/07/078/009-010	Rheumocam	Iceland	18.4.2011
EU/2/07/078/009-010	Rheumocam	Norway	9.2.2011
EU/2/07/078/009-010	Rheumocam	Liechtenstein	28.2.2011
EU/2/07/078/011-014	Rheumocam	Iceland	28.6.2011
EU/2/07/078/011-014	Rheumocam	Liechtenstein	30.6.2011
EU/2/08/082/007	Zactran	Liechtenstein	30.6.2011
EU/2/97/004/041-048	Metacam	Liechtenstein	28.2.2011
EU/2/98/010/025	Econor	Iceland	18.2.2011
EU/2/98/010/025	Econor	Liechtenstein	28.2.2011
EU/99/119/017-018	NovoRapid	Liechtenstein	30.4.2011

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January-30 June 2011:

EU-Number	Product	Country	Date of withdrawal
EU/1/03/259/001-006	Onsenal	Iceland	20.4.2011
EU/1/03/259/001-006	Onsenal	Liechtenstein	30.4.2011
EU/1/05/326/001	Ionsys	Iceland	20.4.2011
EU/1/06/353/001-005	Thelin	Iceland	15.3.2011
EU/1/06/353/001-005	Thelin	Liechtenstein	28.2.2011
EU/1/08/449/001-008	Filgrastim ratiopharm	Liechtenstein	30.4.2011
EU/1/08/449/001-008	Filgrastim ratiopharm	Iceland	12.5.2011
EU/1/09/542/001-007	Clopidogrel 1A Pharma	Liechtenstein	28.2.2011
EU/1/09/542/001-007	Clopidogrel 1A Pharma	Iceland	16.3.2011
EU/1/09/547/001-007	Clopidogrel Sandoz	Liechtenstein	30.4.2011
EU/1/10/629/001	Humenza	Iceland	29.6.2011
EU/1/10/629/001	Humenza	Liechtenstein	30.6.2011

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January-30 June 2011:

EU-Number	Product	Country	Date of suspension
EU/1/00/137/002-018	Avandia	Iceland	13.1.2011
EU/1/03/258/001-022	Avandamet	Iceland	13.1.2011
EU/1/06/349/001-010	Avaglim	Iceland	17.1.2011
EU/2/06/058/001-003	Flexicam	Iceland	14.1.2011
EU/2/08/088/001-003	Acticam	Norway	7.3.2011
EU/2/09/099/001-006	Suvaxyn PCV	Iceland	22.3.2011